Working… Menu

Memokath® 044TW Stent for Treatment of Urethral Stricture

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00270504
Recruitment Status : Completed
First Posted : December 28, 2005
Last Update Posted : November 18, 2009
Information provided by:
Pnn Medical DK

Brief Summary:
The purpose of this study is to evaluate if the placement of a temporary urethral stent for up to 12 months, following dilation or internal urethrotomy (cutting open), results in a higher rate of urethral patency during the first year of follow-up when compared to the control group that does not receive a stent.

Condition or disease Intervention/treatment Phase
Urethral Stricture Device: Memokath stenting Phase 3

Detailed Description:

Patients with bulbar urethral stricture are 2:1 randomised for either urethral dilation or internal urethrotomy with (treatment group) or without (control group) subsequent stenting. All patients are followed for up to one year at 4-6 weeks, 3, 6, 9 and 12 months with visual assessment (urethroscopy) of urethral patency at the treated segment of the urethra. The stent is removed at one year. In case of premature stent removal the patient is also followed for up to one year unless further intervention is decided.

Control patients are offered the stent treatment option if the stricture recurs within the observation period but this group is separately analysed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 92 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective, Randomized, Controlled, Multicenter Trial of the Memokath® 044TW Thermo-Expandable Stent for Maintaining Urethral Patency in Patients After Dilation or Internal Urethrotomy of Recurrent Stricture of the Bulbar Urethra
Study Start Date : December 2002
Actual Primary Completion Date : October 2009
Actual Study Completion Date : November 2009

Intervention Details:
  • Device: Memokath stenting
    Urethral Stenting

Primary Outcome Measures :
  1. Stent/control effectiveness - urethral patency [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Peak urinary flow rate [ Time Frame: Immediate ]
  2. Re-intervention [ Time Frame: Short term ]
  3. Standard survey instruments (QOL, IPSS etc.) [ Time Frame: 15 mos ]
  4. Stent placement success [ Time Frame: immediate ]
  5. Stent removal success [ Time Frame: immediate ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males > 21 years of age
  2. Recurrent stricture of the bulbar urethra:

    1. < 50 mm in length on urethrography; and which
    2. has a segment unable to accommodate a 16Fr flexible cystoscope
  3. Healthy tissue on both sides of stent
  4. Urinary flow in the abnormal range of the Siroky nomogram.
  5. Written informed consent obtained prior to participation in the study
  6. Patients must be available for all follow-up visits.

Exclusion Criteria:

  1. Strictures:

    1. outside the bulbous urethra
    2. associated with, or suspected to be, urethral carcinoma
    3. secondary to pelvic distraction injuries
  2. Inability to enlarge the bulbar urethral stricture to > 26 Fr.
  3. Presence of any other urologic implant
  4. Presence of urethral diverticuli
  5. History of hypospadias repair
  6. Presence or prior history of balanitis xerotica obliterans.
  7. Uncontrolled bleeding disorder
  8. Active urinary tract infection
  9. Any urological condition that would be likely to require additional urethral instrumentation during the period of the investigation, including, but not limited to, benign prostatic hypertrophy requiring treatment; use of alpha blockers; active prostate cancer; an unevaluated elevated prostate-specific antigen (PSA); bladder malignancy; or any recurrent urinary stone formation.
  10. Serum creatinine > 2.0 mg/dl or evidence of progressive renal disease
  11. Concurrent participation in another clinical investigation
  12. Current illness that might confound the results of this investigation
  13. Inability to participate in all of the necessary study activities
  14. Inability or unwillingness to return for all required follow-up visits
  15. Inability or unwillingness to sign the patient informed consent document

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00270504

Layout table for location information
United States, California
Jack McAninch
San Francisco, California, United States, 94110
United States, Mississippi
Mississippi Urology
Jackson, Mississippi, United States, 39202
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
Bryn Mawr Urology
Bryn Mawr, Pennsylvania, United States, 19010
United States, Rhode Island
University Urological Associates
Providence, Rhode Island, United States, 02904
United States, Virginia
Devine-Tidewater Urology
Norfolk, Virginia, United States, 23510
United States, Washington
Harborview Medical Center
Seattle, Washington, United States, 98104
Sponsors and Collaborators
Pnn Medical DK
Layout table for investigator information
Principal Investigator: Gerry Jordan, MD Sentara/Engineers and Doctors
Layout table for additonal information
Responsible Party: Director of Clinical and Regulatory, Pnn Medical Identifier: NCT00270504    
Other Study ID Numbers: 1-044TWUS
First Posted: December 28, 2005    Key Record Dates
Last Update Posted: November 18, 2009
Last Verified: December 2008
Keywords provided by Pnn Medical DK:
Urethral stricture
urethral stent
Bulbar urethral stricture
Additional relevant MeSH terms:
Layout table for MeSH terms
Urethral Stricture
Constriction, Pathologic
Pathological Conditions, Anatomical
Urethral Obstruction
Urethral Diseases
Urologic Diseases